Boston Scientific Future Growth
Future criteria checks 3/6
Boston Scientific is forecast to grow earnings and revenue by 18.1% and 8.7% per annum respectively. EPS is expected to grow by 17.7% per annum. Return on equity is forecast to be 16.7% in 3 years.
Key information
18.1%
Earnings growth rate
17.7%
EPS growth rate
| Medical Equipment earnings growth | 16.2% |
| Revenue growth rate | 8.7% |
| Future return on equity | 16.7% |
| Analyst coverage | Good |
| Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22
Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture
Apr 03Boston Scientific Stands Out With Strong, Diversified Growth Profile
Feb 15Boston Scientific Non-GAAP EPS of $0.45 misses by $0.02, revenue of $3.24B in-line
Feb 01Boston Scientific sees double digit EPS growth in 2023 - JPMorgan Healthcare conference
Jan 11Boston Scientific to acquire majority stake of Acotec Scientific
Dec 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 19,146 | 3,204 | 3,649 | N/A | 24 |
| 12/31/2025 | 17,486 | 2,681 | 3,171 | N/A | 30 |
| 12/31/2024 | 15,979 | 2,145 | 2,232 | N/A | 26 |
| 3/31/2024 | 14,707 | 1,765 | N/A | N/A | N/A |
| 12/31/2023 | 14,240 | 1,570 | 1,822 | 2,503 | N/A |
| 9/30/2023 | 13,757 | 1,191 | 1,736 | 2,353 | N/A |
| 6/30/2023 | 13,400 | 861 | 1,559 | 2,125 | N/A |
| 3/31/2023 | 13,045 | 846 | 1,256 | 1,774 | N/A |
| 12/31/2022 | 12,682 | 642 | 1,008 | 1,526 | N/A |
| 9/30/2022 | 12,567 | 596 | 629 | 1,197 | N/A |
| 6/30/2022 | 12,329 | 828 | 668 | 1,192 | N/A |
| 3/31/2022 | 12,162 | 754 | 1,007 | 1,528 | N/A |
| 12/31/2021 | 11,888 | 985 | 1,398 | 1,870 | N/A |
| 9/30/2021 | 11,470 | 1,101 | 1,701 | 2,065 | N/A |
| 6/30/2021 | 11,196 | 526 | 1,939 | 2,243 | N/A |
| 3/31/2021 | 10,122 | 201 | 1,604 | 1,869 | N/A |
| 12/31/2020 | 9,913 | -115 | 1,219 | 1,508 | N/A |
| 9/30/2020 | 10,108 | 3,685 | 1,242 | 1,527 | N/A |
| 6/30/2020 | 10,157 | 3,980 | 1,008 | 1,386 | N/A |
| 3/31/2020 | 10,785 | 4,287 | 986 | 1,409 | N/A |
| 12/31/2019 | 10,735 | 4,700 | 1,427 | 1,836 | N/A |
| 9/30/2019 | 10,392 | 1,090 | 782 | 1,163 | N/A |
| 6/30/2019 | 10,077 | 1,396 | 826 | 1,162 | N/A |
| 3/31/2019 | 9,937 | 1,797 | 148 | 467 | N/A |
| 12/31/2018 | 9,823 | 1,671 | -6 | 310 | N/A |
| 9/30/2018 | 9,670 | 670 | 686 | 975 | N/A |
| 6/30/2018 | 9,500 | 521 | 653 | 926 | N/A |
| 3/31/2018 | 9,267 | 112 | 1,359 | 1,626 | N/A |
| 12/31/2017 | 9,048 | 104 | N/A | 1,426 | N/A |
| 9/30/2017 | 8,831 | 843 | N/A | 1,418 | N/A |
| 6/30/2017 | 8,714 | 788 | N/A | 935 | N/A |
| 3/31/2017 | 8,582 | 435 | N/A | 1,059 | N/A |
| 12/31/2016 | 8,386 | 347 | N/A | 1,182 | N/A |
| 9/30/2016 | 8,095 | 81 | N/A | 835 | N/A |
| 6/30/2016 | 7,878 | -345 | N/A | 1,274 | N/A |
| 3/31/2016 | 7,595 | -36 | N/A | 913 | N/A |
| 12/31/2015 | 7,477 | -239 | N/A | 691 | N/A |
| 9/30/2015 | 7,314 | -396 | N/A | 711 | N/A |
| 6/30/2015 | 7,272 | -155 | N/A | 649 | N/A |
| 3/31/2015 | 7,302 | -253 | N/A | 874 | N/A |
| 12/31/2014 | 7,308 | -119 | N/A | 1,269 | N/A |
| 9/30/2014 | 7,258 | 288 | N/A | 1,104 | N/A |
| 6/30/2014 | 7,147 | 240 | N/A | 1,009 | N/A |
| 3/31/2014 | 7,083 | 366 | N/A | 1,121 | N/A |
| 12/31/2013 | 7,070 | -121 | N/A | 1,110 | N/A |
| 9/30/2013 | 7,126 | -168 | N/A | 1,204 | N/A |
| 6/30/2013 | 7,125 | -827 | N/A | 1,225 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BSX's forecast earnings growth (18.1% per year) is above the savings rate (2.3%).
Earnings vs Market: BSX's earnings (18.1% per year) are forecast to grow faster than the US market (14.7% per year).
High Growth Earnings: BSX's earnings are forecast to grow, but not significantly.
Revenue vs Market: BSX's revenue (8.7% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: BSX's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BSX's Return on Equity is forecast to be low in 3 years time (16.7%).